Volume 2, Issue 3 (September 2000) 2, 221–224;
KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese
W.L. Hu, Y.Q. Li, H.X. He, Q.R. Li, Y. Tian, R.Q. Lai, H. Mei
Department of Urology, the General Hospital of Guangzhou Military Area, Chinese People's Liberation Army, Guangzhou, China 1.Life Science College, Sun Yat-Sen University, Guangzhou, China 2.First Affiliated Hospital, Sun Yat-Sen University of Medical Sciences, Guangzhou, China
Advance online publication 1 September 2000
Abstract |
Aim: To evaluate KAI1/CD82 expression in Chinese patients with benign prostatic hyperplasia (BPH) and late-stage carcinoma of prostate (CaP). Methods: Thirty Chinese patients with benign prostatic hyperplasia and 34 with CaP (adenocarcinoma clinical stage C and D) were analyzed by means of immunohistochemical methods. Results: The KAI1/CD82 expression in BPH tissue was all positive, which was uniformly located on the glandular cell membrane at the cell-to-cell borders, but KAI1/CD82 expression in metastasis CaP tissues was either significantly lower than that of BPH or negative, and the immunostaining pattern was not continuous. In late-stage CaP KAI1/CD82 expression was correlated inversely to the pathological grade (P<0.05), but not to clinical stage (P>0.05). Conclusion: The authors believe that decreased and negative KAI1/CD82 expression in late-stage CaP may be related to tumor progression and metastasis, and appears to be a prognostic marker.
Full Text |
|
|
Browse: 2127 |
|